Janux Therapeutics price target lowered to $41 from $62 at Scotiabank
See what stocks are receiving Strong Buy ratings from top-rated analysts.
Filter, analyze, and streamline your search for investment opportunities with TipRanks' Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders' Hot Stocks on TipRanks >>
Read More on JANX:
Analyst Recommends 'Buy' for Janux Therapeutics Inc. Amid Share Price Decline and Promising Clinical Outlook
Promising Potential of Janux Therapeutics' Lead Asset and Strategic Plans Justify Buy Rating
Janux Therapeutics price target raised to $76 from $75 at Wedbush
Janux Therapeutics reports Q4 EPS (36c), consensus (45c)
Janux Therapeutics names Zachariah McIver, D.O., Ph.D. as Chief Medical Officer
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
15 hours ago
- Business Insider
SmartCentres Real Estate Investment Trust (SRU.UN) Receives a Hold from Scotiabank
Scotiabank analyst maintained a Hold rating on SmartCentres Real Estate Investment Trust today and set a price target of C$27.50. The company's shares closed today at C$25.97. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. In addition to Scotiabank, SmartCentres Real Estate Investment Trust also received a Hold from BMO Capital's Michael Markidis in a report issued yesterday. However, today, TR | OpenAI – 4o reiterated a Buy rating on SmartCentres Real Estate Investment Trust (TSX: The company has a one-year high of C$27.50 and a one-year low of C$23.18. Currently, SmartCentres Real Estate Investment Trust has an average volume of 277.8K.
Business Wire
6 days ago
- Business Wire
Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)-- Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. 'The recent expansion of our TRACTr, TRACIr, and ARM development programs displays our ability to enact a strategy that attempts to both maximize the benefit and value of our current clinical programs, including JANX007, while continuing to advance other differentiated candidates in oncology and autoimmune disease,' said David Campbell, Ph.D., President and CEO of Janux. 'We look forward to additional clinical data from JANX007 and JANX008 expected in the second half of 2025.' RECENT BUSINESS HIGHLIGHTS AND FUTURE MILESTONES: R&D Day highlighted pipeline progress and novel bispecific platform in autoimmune disease. In July 2025, Janux management presented multiple product candidates identified from its preclinical pipeline to move towards clinical trials. A PSMA-TRACIr designed to be combined with potentially best-in-treatment asset, JANX007, and provide CD28 co-stimulation to further differentiate depth and durability of patient responses. A TROP2-TRACTr added a first-in-class opportunity targeting multiple solid tumors with preclinical data supporting differentiated safety and efficacy potential. A CD19-ARM displayed rapid, deep and durable B-cell depletion in periphery and tissues with a prolonged memory B cell reset while maintaining a large safety window in non-human primates. JANX007 continues to enroll in the first-in-human Phase 1 clinical trial in mCRPC (NCT05519449). JANX008 continues to enroll in the first-in-human Phase 1 clinical trial in advanced or metastatic solid tumors (NCT05783622). Clinical milestone payment of $10 million from Merck recently triggered by first patient dosed in the lead collaboration program under the companies' 2020 Research Collaboration and Exclusive License Agreement. Additional data from JANX007 and JANX008 will be presented at future Janux events in the second half of 2025. Cash and cash equivalents and short-term investments: As of June 30, 2025, Janux reported cash and cash equivalents and short-term investments of $996.0 million, compared to $1.03 billion at December 31, 2024. Research and development expenses: Research and development expenses for the quarter ended June 30, 2025 were $34.7 million, compared to $14.9 million for the comparable period in 2024. General and administrative expenses: General and administrative expenses for the quarter ended June 30, 2025 were $10.5 million, compared to $7.8 million for the comparable period in 2024. Net loss: For the quarter ended June 30, 2025, Janux reported a net loss of $33.9 million, compared to a net loss of $6.0 million for the comparable period in 2024. Janux's TRACTr, TRACIr and ARM Pipeline Janux's first clinical candidate, JANX007, is a TRACTr that targets prostate-specific membrane antigen (PSMA) and is being investigated in a Phase 1 clinical trial in adult patients with mCRPC. Janux's second clinical candidate, JANX008, is a TRACTr that targets epidermal growth factor receptor (EGFR) and is being studied in a Phase 1 clinical trial for the treatment of multiple solid cancers including colorectal carcinoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma and triple-negative breast cancer. Janux is also advancing additional CD3-based TRACTr and CD28-based TRACIr programs for future clinical development, including a PSMA-TRACIr for use in combination with our PSMA-TRACTr JANX007, and a TROP2-TRACTr for the treatment of TROP2+ solid tumors. Janux is advancing its first ARM platform program candidate, a CD19-ARM for the potential treatment of autoimmune diseases toward clinical trials. Janux is also generating a number of additional TRACTr, TRACIr and ARM programs for potential future development. About Janux Therapeutics Janux is a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. Janux has two TRACTr therapeutic candidates in clinical trials, the first targeting PSMA is in development for prostate cancer, and the second targeting EGFR is being developed for colorectal carcinoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma and triple-negative breast cancer. For more information, please visit and follow us on LinkedIn. Forward-Looking Statements This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, Janux's ability to bring new treatments to cancer patients in need, expectations regarding the timing, scope and results of Janux's development activities, including its ongoing and planned preclinical studies and clinical trials, and the potential benefits of Janux's product candidates and platform technologies, expectations regarding the use of Janux's platform technologies to generate novel product candidates and the strength of Janux's balance sheet and the adequacy of cash on hand. Factors that may cause actual results to differ materially include the risk that interim results of a clinical trial are not necessarily indicative of final results and one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data and as more patient data becomes available, including the risk that unconfirmed responses may not ultimately result in confirmed responses to treatment after follow-up evaluations, the risk that compounds that appear promising in early research do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Janux may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings and applications, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words 'may,' 'will,' 'would,' 'could,' 'should,' 'believes,' 'estimates,' 'projects,' 'promise,' 'potential,' 'expects,' 'plans,' 'anticipates,' 'intends,' 'continues,' 'designed,' 'goal,' or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Janux faces, please refer to Janux's periodic and other filings with the Securities and Exchange Commission, which are available at Such forward-looking statements are current only as of the date they are made, and Janux assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Janux Therapeutics, Inc. Unaudited Condensed Statements of Operations and Comprehensive Loss (in thousands, except share and per share data) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Collaboration revenue $ — $ 8,897 $ — $ 10,149 Operating expenses: Research and development 34,664 14,898 59,719 28,968 General and administrative 10,454 7,821 20,296 15,164 Total operating expenses 45,118 22,719 80,015 44,132 Loss from operations (45,118 ) (13,822 ) (80,015 ) (33,983 ) Total other income 11,260 7,863 22,649 13,264 Net loss $ (33,858 ) $ (5,959 ) $ (57,366 ) $ (20,719 ) Other comprehensive gain (loss): Unrealized gain (loss) on available-for-sale securities, net (9 ) (1,092 ) 1,584 (2,281 ) Comprehensive loss $ (33,867 ) $ (7,051 ) $ (55,782 ) $ (23,000 ) Net loss per common share, basic and diluted $ (0.55 ) $ (0.11 ) $ (0.93 ) $ (0.40 ) Weighted-average shares of common stock outstanding, basic and diluted 61,902,411 54,451,666 61,847,372 51,750,690 Expand
Yahoo
6 days ago
- Yahoo
Scotiabank Lifts Price Target for Cheniere Energy (LNG)
Cheniere Energy, Inc. (NYSE:LNG) is one of the 12 Best American Energy Stocks to Buy Right Now. On July 15, Scotiabank increased its price target for Cheniere Energy, Inc. (NYSE:LNG) from $250 to $261 while keeping a Sector Outperform rating. This decision came after the company updated its medium-term outlook in June. The update outlined a plan for Cheniere Energy, Inc. (NYSE:LNG) to reach nameplate production capacity of 100 million tonnes per annum (Mmtpa). It also highlighted prospects for strong cash flow generation. Close-up of a liquefied natural gas terminal expelling plumes of smoke. Additionally, Cheniere Energy, Inc. (NYSE:LNG) announced the final investment decision for its Midscale trains 8 and 9. The company also announced two new brownfield expansions, the SPL Stage V and CCL Stage IV. These expansions will help increase the company's capacity to around 73 Mmtpa. Cheniere Energy, Inc. (NYSE:LNG) is an American energy company that is engaged in liquefied natural gas (LNG)-related businesses. The company is the leading producer and exporter of LNG in the United States. While we acknowledge the potential of LNG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 12 Best Performing AI Stocks So Far in 2025 and 12 Most Owned Stocks by Hedge Funds So Far in 2025. Disclosure: None. This article is originally published at Insider Monkey.
